Clinical trial
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult…
NCT02446912 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT02446912 |
|---|---|
| Title | Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus |
| Official title | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | PRA Health Sciences Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Active Systemic Lupus Erythematosus |
| Intervention type | Biological, Drug |
| Interventions | Anifrolumab, Placebo |
| Enrollment | 460 |
| Start date | Jun 9, 2015 |
| Primary completion | Jul 17, 2018 |
| Completion | Jul 17, 2018 |
| First posted | May 18, 2015 |
| Last update posted | Jan 12, 2023 |
| Countries | Argentina, Australia, Brazil, Chile, Colombia, Germany, Hungary, Israel, Italy, New Zealand, Peru, Poland and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: